Novel insights into the histopathological characteristics of immune checkpoint inhibitor-related myocarditis
Open Access
- 5 May 2026
- journal article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (3)
Abstract
Background and Aims: Pathological examination is commonly used to diagnose immune checkpoint inhibitor (ICI)-related myocarditis. However, well-organized clinicopathological evidence remains limited. In this study, we aimed to investigate the pathological and clinical characteristics of myocarditis to enhance understanding. Methods: This multicentre retrospective observational study included 38 patients diagnosed with or suspected of having ICI-related myocarditis. Patients were stratified using the pathological grading system proposed by Palaskas et al. Lymphocyte infiltration was assessed using both global and hot-spot (hotspot) methods. Immunohistochemistry was performed for lymphocytes, macrophages, and inflammatory markers, including human leucocyte antigen–DR isotype (HLA-DR), programmed death-ligand 1 (PD-L1), granzyme B, and tenascin C. Results: An increased infiltration of CD3, CD4, CD8-positive T cells, and CD68 and CD163-positive macrophages was observed with higher pathological grades. HLA-DR and tenascin C (clone 4F10) were sensitive markers of inflammation, whereas PD-L1 and tenascin C (clone 4C8) were more specific for high-grade inflammation. Global assessment more accurately predicted myocarditis-related mortality than hotspot assessment, although both methods similarly predicted fulminant myocarditis and major adverse cardiac events. Two patients presented with suspected ICI-mediated non-inflammatory left ventricular dysfunction (NILVD), with minimal myocardial inflammation. Conclusions: Pathological grading using both global and hotspot assessment is valuable for the diagnosis and risk stratification of ICI-related myocarditis. As low-grade inflammation is not uncommon, supplementary markers such as HLA-DR, granzyme B, tenascin C, and PD-L1 may aid diagnosis. Furthermore, ICI-mediated NILVD may encompass cases of low-grade myocarditis.Keywords
Funding Information
- JSPS KAKENHI (24K10118)
This publication has 28 references indexed in Scilit:
- 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of MyocarditisJACC, 2024
- Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyEuropean Journal of Heart Failure, 2024
- Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced MyocarditisJACC: Cardiooncology, 2023
- Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapyInternational Cancer Conference Journal, 2023
- A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisCJC Open, 2022
- Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsyEuropean Journal of Heart Failure, 2021
- Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade formsLaboratory Investigation, 2019
- Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseasesInternational Journal of Cardiology, 2019
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsiesJACC, 2002